Experience

Skyward Analytics

• India
• Business Consulting and Services
• 1 - 100 Employee

• Health Economist | Director

  • Aug 2017 - Present

  - Responsible for day to day functioning of the company including but not limited to project specific work, business development, finance, legal and operations - Developed pricing model to assess impact of international reference pricing (IRP) - Developed cost minimisation model for HTA submission in collaboration with another consultancy - Assisted with writing economic section of HTA submission - Developed technical reports and slide decks for models - Conducted data extractions from HTA submissions and other websites - Conducted detailed technical review for health economic models developed externally - Conducted CE model and BIM adaptations for multiple countries - Developed discussion guides to facilitate interviews with clinicians - Provided senior strategic review for a model being developed externally - Developed/reviewed training materials for internal use - Developed, presented and provided review on multiple abstracts, posters and manuscripts Show less



Manipal Academy of Higher Education

• India
• Higher Education
• 700 & Above Employee

• Adjunct Faculty

  • Sep 2019 - Sep 2021

  Adjunct Faculty at the Department of Commerce, MAHE, Manipal for a period of two years. Adjunct Faculty at the Department of Commerce, MAHE, Manipal for a period of two years.



BresMed

• United Kingdom
• Research Services
• 1 - 100 Employee

• Senior Health Economist

  • Nov 2014 - Jul 2017

  Senior member of Health Economic Analysis Team (HEAT) Developed global health economic model for early as well as late stage molecules Built complex model such as patient level simulation, discrete event simulation and treatment sequencing Developed a cost minimisation model and wrote the economic section for manufacturer submission for a NICE MTA in juvenile idiopathic arthritis (JIA) Lead author on an ISPOR abstract evaluating the efficacy and safety for treatments in JIA Developed a Global health economic model for a new drug in relapsing remitting multiple sclerosis (RRMS) Adapted the Global RRMS model for submission for a NICE MTA and SMC. Developed an early economic model to evaluate the use of an investigational drug in systemic sclerosis associated interstitial lung disease (SSc-ILD) Presented model concept at advisory board meeting attended by clinical and health technology assessment (HTA) experts Line management responsibility for India CE team Provided internal training on handling uncertainty in CE models Show less



Accenture

• Ireland
• Business Consulting and Services
• 700 & Above Employee

• Analyst

  • Jan 2014 - Oct 2014

  Member of marketing analytics team Worked on market mix modelling to identify the impact on sales for promotional spend on different mediums Member of marketing analytics team Worked on market mix modelling to identify the impact on sales for promotional spend on different mediums



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Analyst, Health Economic Modeling

  • Apr 2013 - Jan 2014

  Pioneer member of the health economic modeling team set up as part of Global HEOR.Played key role in set-up of modeling team.Worked on an early economic model in cardiovascular risk reductionWorked extensively in multiple sclerosis disease area; built a disability prevention model to assess the benefit of new intervention versus existing treatmentsAssisted with Global model for a new intervention in pathological myopiaCo-authored abstracts and posters presented at EU ISPOR

• Analyst, Health Economic Modeling

  • Jul 2011 - Mar 2013



Deutsche Bank

• Germany
• Financial Services
• 700 & Above Employee

• Summer Intern

  • May 2010 - Jul 2010

  Worked on reducing transaction cost associated with execution of large market orders Accounting for both permanent and temporary Market Impact, determine optimal trading rate conditional on spread, volatility and relative order size to maximize Revenue or minimize Cost while selling/buying shares Worked on reducing transaction cost associated with execution of large market orders Accounting for both permanent and temporary Market Impact, determine optimal trading rate conditional on spread, volatility and relative order size to maximize Revenue or minimize Cost while selling/buying shares